Method for measuring residual quantity of foot-and-mouth disease inactivated vaccine polyethylene glycol 6000 by microscale method
Through the demulsification of n-pentanol, vinyl chloride fat removal and dilution treatment, combined with 96-well flat-bottom enzyme plate and multi-channel pipette, the rapid and efficient problem of the residual amount of polyethylene glycol 6000 in foot-and-mouth disease inactivated vaccine was solved. , improving the stability and quality of the vaccine.
Patent Information
- Application Number
- CN202411430801.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-14
- Publication Date
- 2024-11-12
AI Technical Summary
In the production of inactivated foot-and-mouth disease vaccines, the high residual amount of polyethylene glycol 6000 will lead to vaccine precipitation and side reactions, and there is a lack of fast and efficient measurement methods.
After using n-pentanol demulsification, trichloroethylene fat removal and deionized water dilution, the polyethylene glycol was quickly determined using a 96-well flat-bottom enzyme plate and microplate reader, combined with a multi-channel pipette and EXCEL linear regression equation. 6000 residual amount.
Fast, efficient and accurate measurements are achieved, experimental errors and waste liquid generation are reduced, and vaccine stability and quality are improved.
Smart Images

Figure CN118937667A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of foot-and-mouth disease inactivated vaccine production, in particular to a method for determining the residual amount of polyethylene glycol 6000 in the foot-and-mouth disease inactivated vaccine by micro-measurement. Background Art
[0002] In the production of foot-and-mouth disease inactivated vaccine, when purifying foot-and-mouth disease inactivated antigen, polyethylene glycol 6000 is needed to remove impurities in the intermediate product to increase the content of 146S antigen in foot-and-mouth disease inactivated vaccine, thus causing the problem of polyethylene glycol 6000 residue in foot-and-mouth disease inactivated vaccine. If the residual amount of polyethylene glycol 6000 is too high, it may cause precipitation of foot-and-mouth disease inactivated vaccine, which will seriously affect the stability of foot-and-mouth disease inactivated vaccine and cause certain side effects on immunized animals.
[0003] At present, the national standard for inactivated foot-and-mouth disease vaccines does not specify a method for determining the residual amount of polyethylene glycol 6000. Summary of the invention
[0004] The technical problem to be solved by the present invention is to provide a method for rapidly, efficiently and accurately determining the residual amount of polyethylene glycol 6000 in an inactivated foot-and-mouth disease vaccine by micro-measurement.
[0005] In order to solve the above problems, the method for determining the residual amount of polyethylene glycol 6000 in an inactivated foot-and-mouth disease vaccine by a micro-method according to the present invention comprises the following steps: (1) Demulsifying the foot-and-mouth disease inactivated vaccine sample with n-pentanol to obtain a water phase antigen; degreasing and diluting the water phase antigen with trichloroethylene and deionized water to obtain a treated water phase antigen; ⑵ Accurately measure 200μl of 10μg / ml, 20μg / ml, 30μg / ml, 40μg / ml, 50μg / ml, 60μg / ml, 70μg / ml, 80μg / ml, 90μg / ml polyethylene glycol 6000 series reference solution and treated aqueous antigen into 2ml centrifuge tubes, add 1.0ml of 0.5mol / L perchloric acid solution to each tube, mix well, and leave at room temperature for 15 minutes. 000rpm centrifugation for 10 minutes; take 200μl of the supernatant of the polyethylene glycol 6000 series reference solution of each concentration and the treated aqueous antigen after centrifugation and add it to a 96-well flat-bottom ELISA plate, quickly add 50μl of 5% barium chloride solution and 25μl of 0.1mol / L iodine solution to each well with a multichannel pipette, mix well, and incubate at room temperature for 15 minutes; put the flat-bottom ELISA plate into an ELISA reader, and read each OD value at a wavelength of 535nm; (3) According to the concentration of 10~90μg / ml series of polyethylene glycol 6000 reference solution and its 535nmOD value, use EXCEL to establish a linear regression equation with 535nmOD value as X-axis and polyethylene glycol 6000 reference solution concentration as Y-axis; (4) Substitute the 535nmOD value of the treated aqueous antigen into the linear regression equation to obtain the residual amount of polyethylene glycol 6000, and then calculate the residual amount of polyethylene glycol 6000 in the foot-and-mouth disease inactivated vaccine according to the following formula: ; In the formula: c is the residual amount of polyethylene glycol 6000 in the inactivated foot-and-mouth disease vaccine; w is the residual amount of polyethylene glycol 6000 in the aqueous phase antigen; k is the dilution multiple of the aqueous phase antigen.
[0006] The aqueous phase antigen in the step (1) is prepared according to the following method: 3 mL of the foot-and-mouth disease inactivated vaccine sample is measured and placed in a 10 mL disposable centrifuge tube, 0.3 mL of n-pentanol (n-pentanol: vaccine = 1:10) is added, and the mixture is shaken for 4-5 minutes, and allowed to stand at 2-8° C. for half an hour. After the layers are completely demulsified, 1.0-1.3 mL of the lower aqueous phase is drawn into a 2 mL disposable centrifuge tube using a 2 mL disposable syringe with a flat-head needle to obtain the aqueous phase antigen.
[0007] In step (1), the fat removal is performed as follows: 300 μL of trichloroethylene is added to the aqueous antigen and shaken vigorously for 4 minutes; centrifuged at 3000 g for 15 minutes at 4°C, and about 1 mL of the supernatant in the centrifuge tube is pipetted into a new 2 mL centrifuge tube; the volume ratio of the trichloroethylene to the aqueous antigen is 1:4.
[0008] The dilution in step (1) is performed as follows: the residual amount of polyethylene glycol 6000 in the aqueous phase antigen is estimated. When the estimated residual amount is not higher than 200 μg / ml, no dilution is required; when the estimated residual amount is higher than 200 μg / ml, the degreased aqueous phase antigen is diluted with deionized water so that its polyethylene glycol 6000 content is not higher than 200 μg / ml.
[0009] In the step (2), the polyethylene glycol 6000 series reference substance solution is prepared by the following method: first, accurately weigh 0.0100 g of polyethylene glycol 6000, add water to dissolve it to 100 ml, and obtain 100 μg / ml polyethylene glycol 6000 reference substance mother solution; then, deionized water, a bovine serum albumin solution with a mass concentration of 1%, and 100 μg / ml polyethylene glycol 6000 reference substance mother solution are used to prepare 10-90 μg / ml polyethylene glycol 6000 series reference substance solution according to Table 1; Table 1 Preparation of polyethylene glycol 6000 series reference solution .
[0010] The bovine serum albumin solution with a mass concentration of 1% is obtained by accurately weighing 0.10g of bovine serum albumin and adding deionized water to dissolve it to 10ml.
[0011] Compared with the prior art, the present invention has the following advantages: 1. The present invention uses a multi-channel pipette, which can complete the reagent addition within a few minutes.
[0012] 2. The present invention allows the entire reaction process to be carried out on a flat-bottomed ELISA plate, achieving the purpose of adding samples to the flat-bottomed ELISA plate and quickly reading the data on the ELISA reader after the reaction is completed. At the same time, the room temperature incubation time is unified, and the addition of reaction reagents and reading are carried out simultaneously, which reduces the error caused by the inconsistency of adding reagents and incubation time between samples, making the results accurate and reliable.
[0013] 3. The present invention can measure multiple samples simultaneously, thereby improving the measurement efficiency and reducing the labor intensity of the operator.
[0014] 4. The reference substances, samples and reagents used in the present invention are in trace amounts, so the laboratory waste liquid generated is also small, which greatly reduces the cost of laboratory waste liquid recovery and is beneficial to environmental protection.
[0015] 5. After adopting the method of the present invention, the residual amount of polyethylene glycol 6000 in the foot-and-mouth disease inactivated vaccine can be determined quickly, efficiently and accurately, thereby effectively controlling the residual amount of polyethylene glycol 6000, improving the stability of the foot-and-mouth disease inactivated vaccine, reducing the occurrence of side effects during immunization, and ensuring the quality of the foot-and-mouth disease inactivated vaccine. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] The specific implementation modes of the present invention are further described in detail below in conjunction with the accompanying drawings.
[0017] Figure 1 It is the regression line of polyethylene glycol 6000 in the present invention. DETAILED DESCRIPTION
[0018] A method for determining the residual amount of polyethylene glycol 6000 in an inactivated foot-and-mouth disease vaccine by micro-dosage method comprises the following steps: ⑴ Use n-pentanol to demulsify the foot-and-mouth disease inactivated vaccine sample to obtain the water phase antigen; after the water phase antigen is degreased and diluted with trichloroethylene and deionized water, the treated water phase antigen is obtained. The specific process is as follows: ① Demulsification: Measure 3 mL of inactivated foot-and-mouth disease vaccine sample into a 10 mL disposable centrifuge tube, add 0.3 mL of n-pentanol (n-pentanol: vaccine = 1:10), shake to mix for 4-5 min, let stand at 2-8 °C for half an hour, and after the stratification is completely broken, use a 2 mL disposable syringe with a flat-tipped needle to draw 1.0-1.3 mL of the lower aqueous phase into a 2 mL disposable centrifuge tube to obtain the aqueous phase antigen.
[0019] ② Fat removal: Add 300 μL of trichloroethylene to the aqueous antigen and shake vigorously for 4 minutes; centrifuge at 3000g at 4℃ for 15 minutes, and pipette about 1 mL of the supernatant from the centrifuge tube into a new 2 mL centrifuge tube; the volume ratio of trichloroethylene to aqueous antigen is 1:4.
[0020] ③Dilution: The residual amount of polyethylene glycol 6000 in the aqueous phase antigen is estimated. When the estimated residual amount is not higher than 200 μg / ml, no dilution is required. When the estimated residual amount is higher than 200 μg / ml, the degreased aqueous phase antigen is diluted with deionized water so that its polyethylene glycol 6000 content is not higher than 200 μg / ml, thereby obtaining the treated aqueous phase antigen.
[0021] ⑵ Accurately measure 200μl of 10μg / ml, 20μg / ml, 30μg / ml, 40μg / ml, 50μg / ml, 60μg / ml, 70μg / ml, 80μg / ml, 90μg / ml polyethylene glycol 6000 series reference solution and treated aqueous antigen into 2ml centrifuge tubes, add 1.0ml of 0.5mol / L perchloric acid solution to each tube, mix well, and leave at room temperature for 15 minutes. 000rpm for 10 minutes; take 200μl of the supernatant of the polyethylene glycol 6000 series reference solution of each concentration and the treated aqueous antigen after centrifugation and add it to a 96-well flat-bottom ELISA plate, and quickly add 50μl of 5% barium chloride solution and 25μl of 0.1mol / L iodine solution to each well with a multichannel pipette, mix well, and incubate at room temperature for 15 minutes; put the flat-bottom ELISA plate into an ELISA reader, and read the OD values at a wavelength of 535nm.
[0022] Wherein: the polyethylene glycol 6000 series reference substance solution is prepared as follows: firstly, accurately weigh 0.0100g of polyethylene glycol 6000, add water to dissolve it to 100ml, and obtain 100μg / ml polyethylene glycol 6000 reference substance mother solution; then, deionized water, 1% bovine serum albumin solution and 100μg / ml polyethylene glycol 6000 reference substance mother solution are used to prepare 10~90μg / ml polyethylene glycol 6000 series reference substance solution according to Table 1.
[0023] Table 1 Preparation of polyethylene glycol 6000 series reference solution .
[0024] The bovine serum albumin solution with a mass concentration of 1% is obtained by accurately weighing 0.10g of bovine serum albumin and adding deionized water to dissolve it to 10ml.
[0025] ⑶ According to the concentration of 10~90μg / ml series of polyethylene glycol 6000 reference solution and its 535nmOD value, use EXCEL with 535nmOD value as X-axis and polyethylene glycol 6000 reference concentration as Y-axis to establish a linear regression equation. According to the 535nmOD value of polyethylene glycol 6000 reference solution in Table 2, establish the standard regression line and regression equation of polyethylene glycol 6000 reference solution, as shown in Figure 1 shown.
[0026] Table 2 Absorbance of polyethylene glycol 6000 reference substance (4) Substitute the 535nmOD value of the treated aqueous antigen into the linear regression equation to obtain the residual amount of polyethylene glycol 6000, and then calculate the residual amount of polyethylene glycol 6000 in the foot-and-mouth disease inactivated vaccine according to the following formula: ; In the formula: c is the residual amount of polyethylene glycol 6000 in the inactivated foot-and-mouth disease vaccine; w is the residual amount of polyethylene glycol 6000 in the aqueous phase antigen; k is the dilution multiple of the aqueous phase antigen; 2 is the volume ratio of the aqueous phase antigen to the oil adjuvant, which is about 1:1. Therefore, the residual amount of polyethylene glycol 6000 in the inactivated foot-and-mouth disease vaccine is half of that in its aqueous phase antigen. Example
[0027] Seven samples of inactivated foot-and-mouth disease vaccine were taken and the polyethylene glycol 6000 residue was determined according to the method of the present invention. Each sample of inactivated foot-and-mouth disease vaccine was measured three times, and the polyethylene glycol 6000 residue result, mean value and coefficient of variation were calculated. The results are shown in Table 3.
[0028] After 7 samples of inactivated foot-and-mouth disease vaccine were treated according to step (1) of the present invention, 500 μl of aqueous antigen was taken, 100 μg / ml polyethylene glycol 6000 stock solution was added, mixed, 200 μl was accurately measured, and the polyethylene glycol 6000 residue was determined according to the method of the present invention. The recovery rate was calculated, and the recovery rate was between 95% and 110%. The results are shown in Table 3.
[0029] Table 3 Determination results and recovery rate of polyethylene glycol 6000 residue in inactivated foot-and-mouth disease vaccine
Claims
1. A method for determining the residual amount of polyethylene glycol 6000 in an inactivated foot-and-mouth disease vaccine by a micro-method, comprising the following steps: (1) Demulsifying the foot-and-mouth disease inactivated vaccine sample with n-pentanol to obtain a water phase antigen; degreasing and diluting the water phase antigen with trichloroethylene and deionized water to obtain a treated water phase antigen; ⑵ Accurately measure 200μl of 10μg / ml, 20μg / ml, 30μg / ml, 40μg / ml, 50μg / ml, 60μg / ml, 70μg / ml, 80μg / ml, 90μg / ml polyethylene glycol 6000 series reference solution and treated aqueous antigen into 2ml centrifuge tubes, add 1.0ml of 0.5mol / L perchloric acid solution to each tube, mix well, and leave at room temperature for 15 minutes. 000rpm centrifugation for 10 minutes; take 200μl of the supernatant of the polyethylene glycol 6000 series reference solution of each concentration and the treated aqueous antigen after centrifugation and add it to a 96-well flat-bottom ELISA plate, quickly add 50μl of 5% barium chloride solution and 25μl of 0.1mol / L iodine solution to each well with a multichannel pipette, mix well, and incubate at room temperature for 15 minutes; put the flat-bottom ELISA plate into an ELISA reader, and read each OD value at a wavelength of 535nm; (3) According to the concentration of 10~90μg / ml series of polyethylene glycol 6000 reference solution and its 535nmOD value, use EXCEL to establish a linear regression equation with 535nmOD value as X-axis and polyethylene glycol 6000 reference solution concentration as Y-axis; (4) Substitute the 535nmOD value of the treated aqueous antigen into the linear regression equation to obtain the residual amount of polyethylene glycol 6000, and then calculate the residual amount of polyethylene glycol 6000 in the foot-and-mouth disease inactivated vaccine according to the following formula: ; In the formula: c is the residual amount of polyethylene glycol 6000 in the inactivated foot-and-mouth disease vaccine; w is the residual amount of polyethylene glycol 6000 in the aqueous phase antigen; k is the dilution multiple of the aqueous phase antigen.
2. The method for determining the residual amount of polyethylene glycol 6000 in an inactivated foot-and-mouth disease vaccine by a micro-method as claimed in claim 1, characterized in that: The aqueous phase antigen in the step (1) is prepared according to the following method: 3 mL of the foot-and-mouth disease inactivated vaccine sample is measured and placed in a 10 mL disposable centrifuge tube, 0.3 mL of n-pentanol (n-pentanol: vaccine = 1:10) is added, and the mixture is shaken for 4-5 minutes, and allowed to stand at 2-8° C. for half an hour. After the layers are completely demulsified, 1.0-1.3 mL of the lower aqueous phase is drawn into a 2 mL disposable centrifuge tube using a 2 mL disposable syringe with a flat-head needle to obtain the aqueous phase antigen.
3. The method for determining the residual amount of polyethylene glycol 6000 of foot-and-mouth disease inactivated vaccine by micro-measurement as claimed in claim 1, characterized in that: In step (1), the fat removal is performed as follows: 300 μL of trichloroethylene is added to the aqueous antigen and shaken vigorously for 4 minutes; centrifuged at 3000 g for 15 minutes at 4°C, and about 1 mL of the supernatant in the centrifuge tube is pipetted into a new 2 mL centrifuge tube; the volume ratio of the trichloroethylene to the aqueous antigen is 1:
4.
4. The method for determining the residual amount of polyethylene glycol 6000 of inactivated foot-and-mouth disease vaccine by micro-measurement as claimed in claim 1, characterized in that: The dilution in step (1) is performed as follows: the residual amount of polyethylene glycol 6000 in the aqueous phase antigen is estimated. When the estimated residual amount is not higher than 200 μg / ml, no dilution is required; when the estimated residual amount is higher than 200 μg / ml, the degreased aqueous phase antigen is diluted with deionized water so that its polyethylene glycol 6000 content is not higher than 200 μg / ml.
5. The method for determining the residual amount of polyethylene glycol 6000 in an inactivated foot-and-mouth disease vaccine by a micro-method as claimed in claim 1, characterized in that: In the step (2), the polyethylene glycol 6000 series reference substance solution is prepared by the following method: first, accurately weigh 0.0100 g of polyethylene glycol 6000, add water to dissolve it to 100 ml, and obtain 100 μg / ml polyethylene glycol 6000 reference substance mother solution; then, deionized water, a bovine serum albumin solution with a mass concentration of 1%, and 100 μg / ml polyethylene glycol 6000 reference substance mother solution are used to prepare 10-90 μg / ml polyethylene glycol 6000 series reference substance solution according to Table 1; Table 1 Preparation of polyethylene glycol 6000 series reference solution 。 6. The method for determining the residual amount of polyethylene glycol 6000 in the inactivated foot-and-mouth disease vaccine by micro-measurement as claimed in claim 5, characterized in that: The bovine serum albumin solution with a mass concentration of 1% is obtained by accurately weighing 0.10g of bovine serum albumin and adding deionized water to dissolve it to 10ml.
